Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name file name title title grouped question UIN question first answered answering member label
tabling member	label

Search

718220

	registered interest
	date	06/04/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Social Services: Finance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the allocation of £2 billion of new money for adult social care to be released by 2019–20, what steps they will take to ensure that (1) local government, and (2) representatives of local government, are fully engaged in the preparation of the Green Paper on the funding of adult social care, so that that those responsible for social care locally are able to contribute to the creation of long-term solutions.
	tabling member printed	Lord Porter of Spalding
	uin	HL6720
	answer	answer is ministerial correction date of answer 24/04/2017 answer text <p>Following the announcement of the General Election on 8 June, decisions on the future reform and funding of adult social care will be taken by the new Government.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL6721 question first answered 24/04/2017 11:47:47 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4555 label Biography information for Lord Porter of Spalding

715496

	registered interest
	date	30/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	NHS: Reorganisation
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they intend that rural proofing will be applied to the NHS Sustainability and Transformation Plans.
	tabling member printed	Baroness Byford
	uin	HL6457
	answer	answer is ministerial correction date of answer 06/04/2017 answer text <p>NHS England is aware of <em>Rural proofing: practical guidance to assess impacts of policies on rural areas</em>, published by the Department for Environment, Food and Rural Affairs in March 2017.</p><p> </p><p>All Sustainability and Transformation Plans (STPs) build on the Five Year Forward View to present an overall strategy for their geographic footprint and identify the three to five key priorities required to realise their vision. This should take account of specific challenges facing each area, which could include a dispersed, rural population.</p><p> </p><p>STPs have been in the public domain for several months. Partner organisations within each area are engaging both rural and urban communities on their plans and, where required by law, consulting on service change.</p><p> </p><p>NHS England and NHS Improvement continue to provide ongoing support to each STP area. In September 2016, they published <em>Engaging Local People: A guide for local areas developing Sustainability and Transformation Plans</em>, which set out how STP areas should reach out to stakeholders in their areas. A copy of the guidance is attached.</p><p> </p><p>The NHS is exploring ways to better adapt health provision for rural areas. For example, the vanguard covering Morecambe Bay Health Community is improving healthcare in a geographically isolated area by using a high definition telemedicine link between a general practitioner (GP) surgery in Millom and the accident and emergency (A&amp;E) department in Barrow-in-Furness. This means when GPs can seek a second opinion as to whether a patient needs intensive treatment or can be treated in the community – they can call through and have an A&amp;E specialist examine the patient. This means that over the 1,000 square miles that Morecambe Bay covers, patients can have access to expert opinion without having to travel further than their nearest GP.</p><p> </p><p>On 31 March, <em>Next steps on the NHS Five Year Forward View</em> was published by NHS England. The document outlined a 10-point care and efficiency plan which will further contribute to improving the health outcomes of those living in rural areas. A copy of this document is attached.</p> answering member printed Lord O'Shaughnessy attachment 1 file name engag-local-people-stps.pdf title Engaging Local People 2 file name NEXT-STEPS-ON-THE-NHS-FIVE-YEAR-FORWARD-VIEW.pdf title Next Steps on the Five Year Forward View question first answered 06/04/2017 11:02:39 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	3343 label Biography information for Baroness Byford

718221

	registered interest
	date	06/04/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Social Services: Finance
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what will be the terms of reference for the Green Paper on the funding of adult social care; whether those terms of reference will include all adults who require social care; and when they expect to launch the consultation.
	tabling member printed	Lord Porter of Spalding
	uin	HL6721
	answer	answer is ministerial correction date of answer 24/04/2017 answer text <p>Following the announcement of the General Election on 8 June, decisions on the future reform and funding of adult social care will be taken by the new Government.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL6720 question first answered 24/04/2017 11:47:47 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4555 label Biography information for Lord Porter of Spalding

717922

	registered interest
	date	05/04/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Health Services and Social Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to ensure that there are no legislative barriers to the integration of health and social care services and budgets.
	tabling member printed	Lord Bradley
	uin	HL6669
	answer	answer is ministerial correction date of answer 20/04/2017 answer text <p>The Government is committed to supporting further integration of health and social care. This includes giving due consideration to the need for changes to the legislative framework where this is identified as a barrier to effective integration, and when these changes are in the best interests of the wider health and care system.</p> answering member printed Lord O'Shaughnessy question first answered 20/04/2017 14:37:21 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	452 label Biography information for Lord Bradley

714921

	registered interest
	date	29/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, with reference to paragraphs 2.8, 2.9 and 3.17 of the minutes of 9 March 2017 of the Licence Committee of the Human Fertilisation and Embryology Authority, regarding the follow-up of children born following pronuclear transfer between embryos, who is responsible for the follow-up programme in NHS England; what health, genetic and epigenetic parameters are to be measured; what assessment they have made of the potential for long-term medical problems to only become evident after five years of age; whether they intend to conduct follow-ups beyond five years of age; and whether they will place in the Library of the House a copy of the full documented processes that are in place setting out how follow-ups will be carried out.
	tabling member printed	Lord Alton of Liverpool
	uin	HL6409
	answer	answer is ministerial correction date of answer 06/04/2017 answer text <p>The Human Fertilisation and Embryology Authority has advised that the guidance on the follow up of any children born following mitochondrial donation is set out in paragraph 33.33 in Guidance Note 33 of the Authority’s code of practice. This requires the centre to have a documented process setting out how children born from mitochondrial donation will be followed up, where the patients have consented to follow-up. These should include long-term medical follow-up of the children born. A copy of Guidance Note 33 is attached.</p><p> </p><p>NHS England has agreed funding of £8 million over five years for an evaluative commissioning programme of mitochondrial donation, working closely with the partner organisations such as the Wellcome Trust.</p> answering member printed Lord O'Shaughnessy question first answered 06/04/2017 10:57:08 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name CoP_June_2016_GN33.pdf title Guidance Note 33
	tabling member	738 label Biography information for Lord Alton of Liverpool

714754

	registered interest
	date	28/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, with reference to paragraph 2.8 of the minutes of 9 March 2017 of the Licence Committee of the Human Fertilisation and Embryology Authority (HFEA) regarding babies born following pronuclear transfer between embryos, what procedures are in place to (1) identify whether a child born following pronuclear transfer is born with (a) a mitochondrial disease, (b) a genetic or epigenetic abnormality, (c) a birth defect, or (d) some other adverse outcome, (2) notify the HFEA in cases of any such adverse outcome, and (3) identify any such adverse outcome and notify the HFEA where consent for follow-up has not been granted.
	tabling member printed	Lord Alton of Liverpool
	uin	HL6374
	answer	answer is ministerial correction date of answer 06/04/2017 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that, as set out in Guidance Note 33 of the Authority’s code of practice, centres carrying out mitochondrial donation are required to have documented processes in place setting out how the health of children born from mitochondrial donation will be followed up. A copy of Guidance Note 33 is attached.</p><p> </p><p>If the centre becomes aware that any child born as a result of mitochondrial donation has a mitochondrial disease, birth defect, genetic abnormality or if there has been any other adverse outcome, the centre must report this to the HFEA in accordance with the adverse incidents requirements set out in Guidance Note 27 of the code of practice. A copy of Guidance Note 27 is attached.</p> answering member printed Lord O'Shaughnessy attachment 1 file name CoP_June_2016_GN33.pdf title Guidance Note 33 2 file name CoP_June_2016_GN27.pdf title Guidance Note 27 question first answered 06/04/2017 10:53:18 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	738 label Biography information for Lord Alton of Liverpool

714753

	registered interest
	date	28/03/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, with reference to paragraph 2.3 of the minutes of 9 March 2017 of the Licence Committee of the Human Fertilisation and Embryology Authority, which non-CE marked reagents will be used by Centre 0017 for the purposes of treatment involving pronuclear transfer between embryos to prevent transmission of serious mitochondrial disease; which laboratories will test the non-CE marked reagents for sterility and toxicity; and why non-CE marked reagents are being used.
	tabling member printed	Lord Alton of Liverpool
	uin	HL6373
	answer	answer is ministerial correction date of answer 05/04/2017 answer text <p>The Human Fertilisation and Embryology Authority has advised that it is a condition of a licence that CE marked medical devices must be used wherever possible. In the case of pronuclear transfer, there are no appropriate CE marked reagents, meaning that for treatment to take place, non-CE marked reagents must be used. In this case, the centre must adhere to paragraph 26.5 in Guidance Note 26 of the Authority’s code of practice, which states that if a centre modifies a CE marked product or uses a product “off label”, it must complete a risk assessment and validation to ensure the product is safe. A copy of the Guidance Note 26 is attached.</p> answering member printed Lord O'Shaughnessy question first answered 05/04/2017 14:18:48 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Guidance_Note_26_-_Equipment_and_materials.pdf title Guidance Note 26
	tabling member	738 label Biography information for Lord Alton of Liverpool

718247

	registered interest
	date	06/04/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mesothelioma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 5 April (HL6371), whether they have made any estimate of the cost of mesothelioma to the NHS; and if so, what.
	tabling member printed	Lord Wills
	uin	HL6746
	answer	answer is ministerial correction date of answer 24/04/2017 answer text <p>Neither the Department or its arm’s length bodies have made any formal assessment or estimate about the cost of mesothelioma to the National Health Service.</p> answering member printed Lord O'Shaughnessy question first answered 24/04/2017 13:26:04 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	260 label Biography information for Lord Wills

718246

	registered interest
	date	06/04/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Mesothelioma
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 5 April (HL6371), whether anyone collects any data on the cost of mesothelioma to the NHS; and if so, who.
	tabling member printed	Lord Wills
	uin	HL6745
	answer	answer is ministerial correction date of answer 24/04/2017 answer text <p>While information is not held centrally, individual trusts may capture data relating to the cost of treating mesothelioma patients. However, this information could only be collected at disproportionate cost.</p> answering member printed Lord O'Shaughnessy question first answered 24/04/2017 13:25:13 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	260 label Biography information for Lord Wills

717210

	registered interest
	date	03/04/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Primodos
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Shaughnessy on 28 March (HL6261), whether they will meet with Marie Lyon and representatives of the Primodos victims support group.
	tabling member printed	Lord Alton of Liverpool
	uin	HL6511
	answer	answer is ministerial correction date of answer 06/04/2017 answer text <p>One of the terms of reference of the Expert Working Group on Hormonal Pregnancy Tests is to consider what lessons may be learnt for further improving existing regulatory systems to identify, monitor and minimise any adverse effects of medicines in pregnancy. The regulatory, legal and social landscape has changed significantly since hormonal pregnancy tests were on the market; many of these changes have been driven by previous experience. The Group will consider the processes and tools that were available to the United Kingdom regulator when hormonal pregnancy tests were on the market and make recommendations for any changes necessary to further improve the capability of current regulatory systems to identify, monitor and minimise any adverse effects of medicines in pregnancy. This will include all aspects of medicines regulation, from the assessment of safety pre-authorisation to communication of an identified risk.</p><p>There has been continued engagement with the Association for Children Damaged by Hormonal Pregnancy Tests throughout the Expert Working Group review process. I am meeting the All Party Parliamentary Group on Hormone Pregnancy Tests and representatives of the Association in the near future.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL6515 question first answered 06/04/2017 11:03:19 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	738 label Biography information for Lord Alton of Liverpool